Details

Autor(en) / Beteiligte

• Fakhouri, Fadi
• Fila, Marc
• Hummel, Aurélie
• Ribes, David
• Sellier-Leclerc, Anne-Laure
• Ville, Simon
• Pouteil-Noble, Claire
• Coindre, Jean-Philippe
• Le Quintrec, Moglie
• Rondeau, Eric
• Boyer, Olivia
• Provôt, François
• Djeddi, Djamal
• Hanf, William
• Delmas, Yahsou
• Louillet, Ferielle
• Lahoche, Annie
• Favre, Guillaume
• Châtelet, Valérie
• Launay, Emma Allain
• Presne, Claire
• Zaloszyc, Ariane
• Caillard, Sophie
• Bally, Stéphane
• Raimbourg, Quentin
• Tricot, Leïla
• Mousson, Christiane
• Le Thuaut, Aurélie
• Loirat, Chantal
• Frémeaux-Bacchi, Véronique

Titel

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

Ist Teil von

• Blood, 2021-05, Vol.137 (18), p.2438-2449

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• The optimal duration of eculizumab treatment in patients with atypical hemolytic uremic syndrome (aHUS) remains poorly defined. We conducted a prospective national multicenter open-label study to assess eculizumab discontinuation in children and adults with aHUS. Fifty-five patients (including 19 children) discontinued eculizumab (mean treatment duration, 16.5 months). Twenty-eight patients (51%) had rare variants in complement genes, mostly in MCP (n = 12; 22%), CFH (n = 6; 11%), and CFI (n = 6; 10%). At eculizumab discontinuation, 17 (30%) and 4 patients (7%) had stage 3 and 4 chronic kidney disease, respectively. During follow-up, 13 patients (23%; 6 children and 7 adults) experienced aHUS relapse. In multivariable analysis, female sex and presence of a rare variant in a complement gene were associated with an increased risk of aHUS relapse, whereas requirement for dialysis during a previous episode of acute aHUS was not. In addition, increased sC5b-9 plasma level at eculizumab discontinuation was associated with a higher risk of aHUS relapse in all patients and in the subset of carriers with a complement gene rare variant, both by log-rank test and in multivariable analysis. Of the 13 relapsing patients, all of whom restarted eculizumab, 11 regained their baseline renal function and 2 had a worsening of their preexisting chronic kidney disease, including 1 patient who progressed to end-stage renal disease. A strategy of eculizumab discontinuation in aHUS patients based on complement genetics is reasonable and safe. It improves the management and quality of life of a sizeable proportion of aHUS patients while reducing the cost of treatment. This trial was registered at www.clinicaltrials.gov as #NCT02574403. •Our prospective study shows that in aHUS patients, eculizumab discontinuation based on complement genetics is reasonable and safe.•This discontinuation strategy improves the management and quality of life of many aHUS patients while reducing the cost of treatment. [Display omitted]